Skip to main content
Fig. 2 | Breast Cancer Research

Fig. 2

From: Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers

Fig. 2

Anti-tumor effects of PS and PD-1 targeting alone and in combination in murine BC models. a Top panel: growth kinetics of E0771 TNBC tumors in C57/Bl6 mice treated with control (C44 ), mch1N11, anti-PD-1, or mch1N11 + anti-PD-1 antibody combinations. Treatments started at 10 days post inoculation when tumors were approximately 100 mm3. All data points are expressed as median and SD. Bottom panel: analysis of E0771 final tumor volumes from the TGI study in upper panel. Statistical analysis (Student’s t test) demonstrates that combinational treatment with PS-targeting antibody and ant-PD-1 antibody has significant inhibitory effects compared with all other treatments. b Top panel: growth kinetics of EMT-6 murine breast tumors in Balb/c mice treated with control (C44), mch1N11, anti-PD-1, or mch1N11 + anti-PD-1 antibody combinations. Treatments started at 3 days post inoculation when tumors were approximately 100 mm3. All data points are expressed as median and SD. Bottom panel: analysis of EMT-6 final tumor volumes from TGI study in upper panel. Statistical analysis demonstrates that combinational treatment with PS-targeting antibody and anti-PD-1 antibody has significant inhibitory effects compared with all other treatments. Statistically significant differences between groups were identified by Student’s t test, with 10 animals in each group. TGI tumor growth inhibition

Back to article page
\